Highlights from Lumen’s big new collaboration with CARB-X, A-Alpha, Tufts University, and the US Naval Medical Research Center

By Brian Finrow and Jim Roberts

A component of Lumen Bio’s cGMP antibody drug manufacturing plant. (Photo by Arianna Lewellyn.)

Delhi belly. Montezuma’s Revenge. The Aztec two-step. Here in the West, we like to slap whimsical names on traveler’s diarrhea. For those of us blessed with ready access to food and sanitary infrastructure, these diseases are a minor inconvenience.

Those in the developing world are not so lucky: diarrhea kills hundreds of thousands of people each year, most often infants and newborns. Traveler’s diarrhea is also a major concern for antimicrobial resistance. Antibiotic-resistant strains are on the rise, and over-use of antibiotics is thought to encourage the emergence and spread of new ones. …

Brian Finrow

Jim and I started Lumen Bioscience in 2017 to develop and commercialize ultra-low-cost biologics.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store